BRISTOL-MYERS SQUIBB COMPANY (NYSE:BMY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

BRISTOL-MYERS SQUIBB COMPANY (NYSE:BMY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Story continues below

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

(b) On December 19, 2016, Lamberto Andreotti notified
Bristol-Myers Squibb Company (the Company) that he will not stand
for re-election to the Board of Directors at the 2017 Annual
Meeting of Stockholders, which is expected to be held on May 2,
2017.
Additionally, on December 21, 2016, the Company announced that
the Board of Directors has elected Giovanni Caforio, M.D., the
Chief Executive Officer of the Company, to become Chairman of the
Board effective May 2, 2017. Dr. Caforio will serve as both
Chairman of the Board and Chief Executive Officer of the Company.
A copy of the press release announcing the retirement of Lamberto
Andreotti from the Board and the election of Giovanni Caforio,
M.D. as Chairman of the Board is attached to this report as
Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1
Press release dated December 21, 2016


About BRISTOL-MYERS SQUIBB COMPANY (NYSE:BMY)

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.

BRISTOL-MYERS SQUIBB COMPANY (NYSE:BMY) Recent Trading Information

BRISTOL-MYERS SQUIBB COMPANY (NYSE:BMY) closed its last trading session down -0.43 at 58.69 with 4,431,371 shares trading hands.

An ad to help with our costs